Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Turkey / NCT07420088
Recruiting Observational

Seasonal Physical Activity in Patients With Heart Failure With Cardiac Implantable Electronic Devices

NCT07420088 · tracked via the Priya Life Science Turkey tracker
Sponsor
Erol Olcok Corum Training and Research Hospital
Phase
Observational
Started
2026-01-21
Last updated
2026-05-08

Condition(s) studied

Heart FailureCardiac Implantable Electrical DevicesPhysical Activities

Investigational drug(s) / intervention(s)

follow-up study

follow-up study: Seasonal variations in physical activity will be objectively investigated in heart failure patients with implantable cardiac electronic devices.

Study summary

The aim of this observational study is to determine the effect of seasonal changes on physical activity levels in heart failure patients with cardiac implantable electronic devices.

Patients with heart failure who have a cardiac implantable electronic device will be evaluated throughout the year.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Over 18 years of age, * Have a diagnosis of heart failure due to ischemic or non-ischemic cardiomyopathy, * Have a cardiac implantable electrical devices, * Be in New York Heart Association (NYHA) Class I-II-III. Exclusion Criteria: * Being a New York Heart Association (NYHA) Class IV resident * Not living within a 50-mile radius of a weather reporting station, * Having documented conditions that limit ambulation, including wheelchair use, serious orthopedic problems, stroke and other neurological disorders, or amputation, * Using a left ventricular assist device, * Having a history of more than five hospitalizations for any reason, * Having recently undergone major cardiovascular or orthopedic surgical procedures, including coronary artery bypass grafting, aortic aneurysm repair, joint replacement, amputation, or spinal surgery, * Having a cognitive impairment that impairs cooperation with questionnaires or tests.

Primary outcome measure(s)

  • Participant's objective physical activity level — Every three months for one year (Patients will be evaluated in all four seasons: spring, summer, autumn, and winter)
    Objective measurement of physical activity will be assessed using an accelerometer (Garmin Vivosmart 5). The accelerometer will be placed on the patient's non-dominant wrist for one week, 5 days a week during weekdays and 2 days a week on weekends. The accelerometer can be used day and night, while sleeping or showering, and has enough battery life to collect activity data throughout the day.
  • Participant's subjective physical activity level — Every three months for one year (Patients will be evaluated in all four seasons: spring, summer, autumn, and winter)
    Additionally, physical activity will be assessed using International Pyhsical Activity Questionnaire Short Form (IPAQ). The questionnaire examines physical activity in four different groups: vigorous physical activity, moderate physical activity, walking, and sitting. In the results evaluation, the data is converted to metabolic rate (MET) values and calculated accordingly.

Trial sites (1)

FacilityCityRegionStatus
Hitit University Erol Olcok Training and Research Hospital Çorum Turkey (Türkiye) Recruiting

More Erol Olcok Corum Training and Research Hospital trials in Turkey

Comparison of the Effects of Different Upper Extremity Aerobic Exercise Training Protocols on Arm Functional Capacity in Patients With Heart Failure With Cardiac Implantable Electronic Devices Recruiting

Other trials for the same condition

Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin Recruiting
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure Recruiting
THE RELATİONSHİP BETWEEN BLOOD GAS PARAMETERS OBTAİNED FROM THE CORONARY SİNUS DURİNG THE PROCEDURE AND CRT RESPONSE İN PATİENTS WİTH HEART FAİLURE WHO UNDERWENT CRT IMPLANTATİON Active, not recruiting
The AFteR Registry - Follow-up Study to Monitor the Efficacy and Safety of the Occlutech AFR in Heart Failure Patients Recruiting
Echocardiography-Based Predictors of Outcomes in Hospitalized Patients With Decompensated Heart Failure (ECHO-DECOMP) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07420088 on ClinicalTrials.gov ↗ ← All trials in Turkey